Shatavari: An Emerging Ingredient in Women’s Wellness

Shatavari (Asparagus racemosus) is an Ayurvedic botanical with a long history of traditional use in women’s health. New clinical trials have brought it into current conversations about sexual wellness, but the findings are early and tied to particular extracts, not a blanket endorsement of every shatavari supplement.

For women considering a supplement and brands evaluating the ingredient, the distinction matters: traditional use provides context, clinical studies offer preliminary evidence, and neither alone establishes that every product will have the same effects.

From traditional use to emerging research

In Ayurvedic tradition, shatavari is described as a rasayana. A botanical category associated with rejuvenation and well-being. It has also been used traditionally in connection with menstrual and lactation health. These traditional uses are part of the plant’s history; they do not establish modern clinical efficacy or safety for a specific product or life stage.

The newer research has focused on sexual-wellness measures, including the Female Sexual Function Index (FSFI), a self-reported questionnaire assessing domains such as desire, arousal, lubrication, orgasm, satisfaction and pain. Two recent randomized, placebo-controlled trials provide preliminary findings.

In a trial published in the Journal of Medicine and Life, 70 women aged 18–45 with self-reported low sexual desire were assigned to receive 300 mg per day of a shatavari root extract or placebo for eight weeks. The extract was a specific branded product, standardized to 5% total shatavarins. The researchers reported a greater improvement in total FSFI score with the extract than with placebo; the reported between-group difference at day 56 was 3.3 points (95% CI 1.6–5.0; P=.001). Improvements in measures of vaginal moisture, fatigue, sleep disturbance and psychosocial well-being were also reported. Three participants did not complete the study.

A separate three-arm study, registered as NCT06972706, enrolled 135 women and compared a different shatavari root extract, shatavari combined with ashwagandha, and placebo over eight weeks. The tested shatavari dose was 300 mg daily; the combination arm also received 250 mg of ashwagandha root extract. The extract used in this trial had a different specification: a 13:1 herb-to-extract ratio and more than 10% total shatavarins by HPLC, as described by the researchers.

Among participants in the per-protocol analysis, shatavari alone and the combination both improved total FSFI scores versus placebo. The combination showed differences from placebo in some additional measures, including arousal, lubrication, orgasm and sexual distress. However, total FSFI improvement did not significantly differ between the two active groups. These findings do not establish that combining the ingredients is generally superior.

What the studies do, and do not, show

Both trials are encouraging signals, not definitive proof. Each lasted eight weeks, included a relatively small group, and relied substantially on participant-reported outcomes. The three-arm trial also assessed multiple secondary outcomes and noted that its results should be interpreted cautiously. Neither trial establishes long-term effectiveness or safety, or that shatavari treats a diagnosed sexual-health condition.

The tested extracts also differ in standardization, which makes direct comparison difficult. A dose of 300 mg of one extract cannot automatically be treated as equivalent to 300 mg of another: concentration, extraction method, plant material and marker specifications can vary.

The participant groups deserve attention, too. The studies included women aged 18–45 and 18–55, respectively, but they do not demonstrate that the same results apply specifically to women over 40, women in perimenopause, or women with a particular underlying cause of sexual-health changes. Sexual well-being can be influenced by many factors. Persistent changes, pain, dryness or distress merit discussion with a qualified healthcare professional rather than self-diagnosis or self-treatment.

Formulation quality starts with ingredient identity

For supplement brands, the clinical question is not simply whether a label lists shatavari. It is whether the ingredient in the finished product is well-defined, consistent and suited to the intended formulation.

A development specification may include authenticated A. racemosus root, the plant part used, extract ratio, extraction solvent and a defined chromatographic fingerprint. Shatavarin content is one possible standardization measure; analytical literature describes methods for measuring individual markers such as shatavarin IV. The selected marker and method should be appropriate for the ingredient being sourced and should not be presented as proof that a new extract is clinically equivalent to one used in a trial.

Sarsasapogenin may also be considered within a broader analytical approach, but a single marker should not stand in for botanical identity, extract composition or clinical equivalence. Supplier documentation is useful, but specifications should be paired with appropriate identity testing and checks for contaminants, including heavy metals, pesticides, residual solvents and microbial impurities. Finished-product testing and stability data help confirm that the ingredient remains within specification through its intended shelf life.

These controls are part of responsible supplement manufacturing. Under 21 CFR Part 111, dietary supplement manufacturers must establish specifications and use scientifically valid methods to determine whether they are met.

Dosage form, taste and stability

The available trials tested capsules. That does not mean the same dose or study findings automatically transfer to powders, liquids or gummies. Each format introduces practical and quality considerations, and any reformulation needs its own evaluation.

Shatavari’s botanical flavor and powder characteristics can affect consumer acceptance, particularly in chewable or gummy products. Development work may need to assess taste masking, texture, ingredient compatibility and serving size. A gummy’s available space, for example, can constrain how much extract fits alongside sweeteners, acids, flavors and other active ingredients. Stability testing can help assess whether the botanical’s measured constituents remain consistent over time in the selected formula and packaging.

Claims: keep the evidence and wording aligned

In the United States, dietary supplement structure/function claims must be truthful, not misleading and substantiated. The FDA’s guidance on structure/function claims explains the notification and disclaimer requirements that apply to these claims. Advertising is also subject to FTC guidance, which requires health-related claims to be supported by adequate scientific evidence.

For shatavari, a defensible claims strategy should reflect the specific product, dose, evidence and intended audience. Trial outcomes for a standardized extract do not substantiate the same claims for every shatavari powder or blend. Claims that imply treatment of a disease or diagnosed condition require particular caution, as do broad statements about hormone balancing, menopause symptoms, fertility or sexual dysfunction. Regulatory and legal review is recommended before packaging, website copy or promotional content is finalized.

Safety considerations for women and brands

The short trials reported no serious adverse events, but this does not establish safety for long-term use or for every population. Women who are pregnant or breastfeeding, take medications, have an ongoing health condition or have questions about symptoms should seek advice from a qualified healthcare professional before using shatavari. Because it has traditional associations with menstrual and lactation health, pregnancy and breastfeeding questions deserve particular care; traditional use is not a substitute for individualized professional guidance.

A considered approach to a developing ingredient

Shatavari is a traditional botanical with emerging clinical evidence in sexual wellness. Two short trials reported improvements in some measured outcomes using specific, standardized extracts and doses. The results are worth following, but they do not prove that all shatavari products perform alike, establish long-term benefits, or show that the ingredient treats a condition.

For brands, careful ingredient identity, clear specifications, suitable testing and evidence-matched claims are central to responsible product development. SolisLabs supports nutraceutical projects from formulation through production and packaging. Its manufacturing services include custom development across capsules, powders, liquids and tablets; powder manufacturing is one option for teams evaluating a flavored format. Product concepts and ingredient specifications can be discussed through the SolisLabs contact page.